Omeros Corp OMER
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA
-
Omeros Corporation Reports Second Quarter 2026 Financial Results
-
Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026
-
CMS Grants New Technology Add-On Payment (NTAP) Status to YARTEMLEA®
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
-
Omeros Gets FDA Approval of Yartemlea
-
Novo Nordisk to Buy Blood Disease Drug From Omeros for Up to $2.1 Billion — Update
Trading Information
- Previous Close Price
- $18.79
- Day Range
- $15.85–17.94
- 52-Week Range
- $6.24–21.24
- Bid/Ask
- $16.25 / $16.40
- Shares Outstanding
- 72.39M
- Market Cap
- $1.17B
- Volume/Avg
- 4M / 2M
Key Statistics
- Price/Earnings (Normalized)
- 17.25
- Price/Sales
- 38.96
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 175
- Website
- https://www.omeros.com
Valuation
|
Metric
|
OMER
|
|---|---|
Price/Earnings (Normalized) | 17.25 |
Price/Book Value | — |
Price/Sales | 38.96 |
Price/Cash Flow | — |
Price/Earnings
OMER
Financial Strength
|
Metric
|
OMER
|
|---|---|
Quick Ratio | 1.88 |
Current Ratio | 1.95 |
Interest Coverage | 117.76 |
Quick Ratio
OMER
Profitability
|
Metric
|
OMER
|
|---|---|
Return on Assets (Normalized) | −12.70% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −73.07% |
Return on Assets
OMER
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|@@>g%#l | LOCK|^D@Y! | $127B | |||
| Moderna Inc
MRNA
| LOCK|<W!L<q | LOCK|zBf | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|%hd$^% | LOCK|@^g^ | $81B | |||
| argenx SE ADR
ARGX
| LOCK|Kv?#j>b | LOCK|YQX | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|^G$x^! | LOCK|!> | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|>pf^hGX | LOCK|Vl^SF | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|L<!<?sv | LOCK|SJ%& | $27B | |||
| Incyte Corp
INCY
| LOCK|<fS&L< | LOCK|BD | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|T&n$L$ | LOCK|S% | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|sr!#<?s | LOCK|Vm | $14B |
United States